200
Participants
Start Date
October 19, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
AlloMend® Acellular Dermal Matrix allograft
AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
RECRUITING
Alan H. Chen Surgical Associates, PC, Joliet
Lead Sponsor
AlloSource
INDUSTRY